Targeting IL1β signaling, for example, by using antibodies (canakinumab), to treat PAD has been tested in a randomized controlled clinical trial and was found to improve the maximum and pain-free walking distance in patients with symptomatic PAD [43]. Here, IL1B is linked to peripheral arterial disease.